Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

NCT05887726 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Epirubicin
DRUG: Vincristine
DRUG: Prednisone

Sponsor

Liaoning Cancer Hospital & Institute